EHA 2018 - Prof. dr. S. Verstovsek - EXPAND (video)

Presenter: Prof. dr. Srdan Verstovsek, MD Anderson, Houston (US)

RESULTS FROM 48-WEEK FOLLOW-UP OF THE EXPAND STUDY: A PHASE 1B, OPEN-LABEL, DOSE-FINDING STUDY OF RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS AND LOW PLATELET COUNTS (50-99 × 10^9/L) AT BASELINE

 

Klik hier voor het abstract

 

Click here for the prescribing information of Jakavi
 

0419HEM1151436
×

Ask Speakers

×

Medical Information Request